Illumina Inc
About Illumina Inc
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
- Ticker
- ILMN
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Diagnostics & Research
- Sector
- Healthcare
- CEO
- Jacob Thaysen Ph.D.
- Headquarters
- 5200 Illumina Way, San Diego, CA, United States, 92122
- Employees
- 8,600
- Website
- illumina.com
Metrics
Analyst Insights & forecasts
Based on information from 21 analysts.
Earnings per share (EPS) forecast
| Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|
| Actual | $1.35 | $1.15 | $1.31 |
| Expected | $1.23 | $1.06 | $1.23 |
| Surprise | 9.76% | 8.49% | 6.50% |
| Beat | Beat | Current |
Financial Performance
| Q2 • 26 | Q3 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $1.16B | $1.13B | -2.59% |
| Net income | $207M | $220M | 6.28% |
| Profit margin | 17.86% | 19.49% | 9.10% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a Illumina Inc share?
Illumina Inc shares are currently traded for undefined per share.
02How many shares does Illumina Inc have?
Illumina Inc currently has 151M shares.
03Does Illumina Inc pay dividends?
No, Illumina Inc doesn't pay dividends.
04What is Illumina Inc 52 week high?
Illumina Inc 52 week high is $309.35.
05What is Illumina Inc 52 week low?
Illumina Inc 52 week low is $112.65.
06What is the 200-day moving average of Illumina Inc?
Illumina Inc 200-day moving average is $180.09.
07Who is Illumina Inc CEO?
The CEO of Illumina Inc is Jacob Thaysen Ph.D..
08How many employees Illumina Inc has?
Illumina Inc has 8,600 employees.
09What is the market cap of Illumina Inc?
The market cap of Illumina Inc is $31.8B.
10What is the P/E of Illumina Inc?
The current P/E of Illumina Inc is 36.15.
11What is the EPS of Illumina Inc?
The EPS of Illumina Inc is $5.81.
12What is the PEG Ratio of Illumina Inc?
The PEG Ratio of Illumina Inc is 2.49.
13What do analysts say about Illumina Inc?
According to the analysts Illumina Inc is considered a buy.


